HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Consumers should refrain from using soap and other products containing triclosan and other biocides at home, according to the Federal Institute for Risk Assessment, a new scientific body of the Federal Republic of Germany. Noting consumer products contain only low doses of triclosan insufficient to kill bacterial pathogens, FIRA adds, "When it comes to everyday life, soap and water or conventional cleansing products are quite capable of achieving the same effect." The institute expressed concern over the risk of increasing resistance of microorganisms to the ingredient, and concluded products containing triclosan should only be used in clinics and doctors' offices. Antibacterial resistance associated with triclosan use has been a topic of increasing interest in the U.S. In October, FDA's Nonprescription Drugs Advisory Committee unanimously agreed that makers of non-alcohol-based antimicrobials should be required to demonstrate products' clinical benefit prior to sale (1"The Rose Sheet" Oct. 24, 2005, p. 9)...

You may also be interested in...

Non-Alcohol Antiseptic Hand Products Should Prove Efficacy – NDAC

Marketers of non-alcohol-based consumer antiseptic products should be required to prove their products provide clinical benefit prior to sale, an FDA advisory panel unanimously agreed Oct. 20

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts